Binciken daurin furotin na Spike da ƙididdigar neutralization ta amfani da ƙwayoyin cuta da ke wakiltar duk sanannun bambance-bambancen SARS-CoV-2 na damuwa (VOCs) an kammala su tare da STI-9167, kuma an lura da wannan nAb don ɗaure tare da babban kusanci kuma yana ba da aiki mai ƙarfi mai ƙarfi (Omicron IC50). = 25 ng/ml. Daga cikin mahimmancin mahimmanci, STI-9167 na musamman ne idan aka kwatanta da gwaje-gwaje na EUA-amince da SARS-CoV-2 nAbs a cikin cewa an kiyaye kaddarorin dauri da kaddarorin a kan bambance-bambancen Omicron da Omicron (+ R346K) da ke fitowa, bambance-bambancen layin Omicron wanda ke haɓaka. yana sanya ƙarin maye gurbi na sunadaran R346K Spike. Bugu da ƙari, STI-9167 ana gudanar da shi a ƙaramin kashi (5mg/kg) ta ko dai hanyoyin ciki ko na ciki sun ba da kariya mai ƙarfi daga alamun kamuwa da cuta ta bambance-bambancen Omicron a cikin K18-hAce2 transgenic linzamin kwamfuta model na COVID-19, hana nauyi. asara da rage titers a cikin huhu zuwa matakan da ba za a iya gano su ba.

"Tsarin da kuma halayen STI-9167 nAb ya nuna babban haɗin gwiwa tsakanin masana kimiyya na Dutsen Sinai da Sorrento don magance matsalar lafiyar duniya," in ji Domenico Tortorella, PhD, Farfesa na Microbiology a Icahn Mount Sinai.

"Mun zaɓi rigakafin STI-9167 daga manyan nau'ikan anti-SARS-CoV-2 spike kawar da ƙwayoyin rigakafi waɗanda muka haɓaka a cikin labs ɗin mu. Ya nuna mafi kyawun tsaka-tsakin tsaka-tsaki a kan duk sanannun keɓewar SARS-CoV-2 da bambance-bambancen damuwa, gami da bambance-bambancen Omicron da Omicron (+ R346K) na baya-bayan nan, ”in ji J. Andrew Duty, PhD, Mataimakin Farfesa na Microbiology kuma Daraktan Cibiyar Ci Gaban Ƙwararrun Jiki a Icahn Dutsen Sinai.

Mike A. Royal, MD, JD, MBA, Babban Jami'in Kiwon Lafiyar Jama'a a yanzu ya ce "A halin yanzu EU-an yarda da nAbs sun ragu sosai ko kuma ba su da alaƙa da ayyukan kawar da omicron/omicron (+ R346K) Sorrento. "Ana buƙatar madadin nAbs a cikin ɗan lokaci kaɗan, musamman ga yawan yaran yara waɗanda ke da alama suna cikin haɗari mafi girma don kamuwa da cutar omicron da asibiti. Tsarin mu na ciki na COVIDROPS yana isar da nAbs zuwa manyan hanyoyin iska inda Omicron ya fi dacewa ya yi niyya kuma ya bunƙasa, kuma a matsayin mara cin zarafi, mai sauƙin gudanar da magani, ya dace da yara. Mun riga mun fara jinyar yara masu COVIDROPS (tare da STI-2099) a Mexico inda har yanzu bambance-bambancen delta ke yaduwa. Ta hanyar nazarin mataki na 2 a cikin Amurka, United Kingdom da Mexico, mun ga ingantaccen bayanin martaba na aminci don isar da saƙo na nAbs ɗin mu kuma muna tsammanin sakamako mai kama da COVIDROP (tare da STI-9167)."

"Yanzu mun sami gogewa tare da kawo magungunan COVID-19 da yawa a cikin asibitin da haɓaka da yawa zuwa Mataki na 2 da / ko ci gaba mai mahimmanci," in ji Mark Brunswick, PhD, SVP da Shugaban Al'amuran Gudanarwa da Inganci a Sorrento. "Muna da kyau don fitar da COVISHIELD cikin sauri ta hanyar IND da kuma cikin asibitin kuma muna sa ran shigar da wannan muhimmin IND a wata mai zuwa."

Dr. Henry Ji, Shugaban da Shugaba na Sorrento, yayi sharhi, "Ayyukan da ƙungiyoyin suka yi a Sorrento da Dutsen Sinai sun samar da wani babban rigakafin rigakafi tare da keɓaɓɓen kaddarorin kariya masu mahimmanci ga Omicron da duk sauran SARS-CoV-2 VOCs. Mu COVISHIELD neutralizing antibody shine mafi kyawun aji kuma mafi girman ɗan takara don yaƙar Omicron da ke fitowa da Omicron (+ R346K) VOCs. Muna aiki tuƙuru don sanya wannan rigakafin don amfani a cikin marasa lafiya na COVID kuma muna da tabbacin cewa hanyarmu za ta samar da ingantaccen maganin asibiti ba kawai a cikin ɗan gajeren lokaci ba har ma yayin da cutar ke ci gaba da haɓaka. ”

An ƙaddamar da rubutun riga-kafi a ranar 19 ga Janairu, 2022 kuma za a buga shi nan da nan akan layi a biorxiv.org.

An samar da maganin rigakafin da aka kwatanta a cikin dakunan gwaje-gwaje a Dutsen Sinai kuma an ba shi lasisi na musamman ga Sorrento Therapeutics. Jami'an tsaunukan Sinai da Dutsen Sinai suna da sha'awar kuɗi a Sorrento Therapeutics.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

Additionally, STI-9167 administered at a low dose (5mg/kg) by either the intranasal or intravenous routes provided strong protection against the clinical signs of infection by the Omicron variant in the K18-hAce2 transgenic mouse model of COVID-19, preventing weight loss and reducing virus titers in the lungs to undetectable levels.
Of noted significance, STI-9167 is unique when compared to tests of EUA-approved SARS-CoV-2 nAbs in that binding and neutralization properties are maintained against the emerging Omicron and Omicron (+R346K) variant, an increasingly prevalent Omicron lineage variant that encodes an additional R346K Spike protein mutation.
Our intranasal COVIDROPS formulation delivers our nAbs to the upper airways where Omicron is most likely to target and flourish, and as a non-invasive, easy to administer treatment, it is ideal for children.